Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

Yoichi Nakanishi, Koichi Takayama, Koichi Takano, Kohji Inoue, Shin'ichi Osaki, Hiroshi Wataya, Youichi Takaki, Takahiro Minami, Masayuki Kawasaki, Nobuyuki Hara

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cisplatin and irinotecan are reported to act synergistically. The authors have conducted a phase II trial combining cisplatin and irinotecan in patients with refractory lung cancer to evaluate the activity and safety of the regimen. Twenty-one patients, who had not responded to prior platinum- based chemotherapy, were entered into the study. Both cisplatin (30 mg/m2) and irinotecan (60 mg/m2) were administrated on days 1, 8, and 15, and the regimen was repeated every 28 days. There were six partial responses, and the response rate was 29% (95% confidence interval, 11.3%-52.2%). The median survival time of all patients was 32 weeks, and 1-year and 2-year survival rates were 43% and 11%, respectively. Major toxicities were hematologic; leukopenia of grades 3 and 4 developed in 43% patients, anemia developed in 38%, and thrombocytopenia developed in 19%. One notable nonhematologic toxicity was diarrhea; which was grade 3 in 38%. The weekly chemotherapy combining cisplatin and irinotecan was active against lung cancer, which is refractory to platinum-based chemotherapy. However, skips of drag administration or dose reduction were necessary in 76% patients during two courses of planned administration, though the ratio of actual dose to scheduled dose was 81%. Dose modification would be necessary to yield better results by this weekly chemotherapy.

Original languageEnglish
Pages (from-to)399-402
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number4
DOIs
Publication statusPublished - Aug 1 1999

Fingerprint

irinotecan
Cisplatin
Lung Neoplasms
Drug Therapy
Platinum
Leukopenia
Thrombocytopenia
Anemia
Diarrhea
Survival Rate
Confidence Intervals
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. / Nakanishi, Yoichi; Takayama, Koichi; Takano, Koichi; Inoue, Kohji; Osaki, Shin'ichi; Wataya, Hiroshi; Takaki, Youichi; Minami, Takahiro; Kawasaki, Masayuki; Hara, Nobuyuki.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 22, No. 4, 01.08.1999, p. 399-402.

Research output: Contribution to journalArticle

Nakanishi, Y, Takayama, K, Takano, K, Inoue, K, Osaki, S, Wataya, H, Takaki, Y, Minami, T, Kawasaki, M & Hara, N 1999, 'Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 22, no. 4, pp. 399-402. https://doi.org/10.1097/00000421-199908000-00016
Nakanishi, Yoichi ; Takayama, Koichi ; Takano, Koichi ; Inoue, Kohji ; Osaki, Shin'ichi ; Wataya, Hiroshi ; Takaki, Youichi ; Minami, Takahiro ; Kawasaki, Masayuki ; Hara, Nobuyuki. / Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1999 ; Vol. 22, No. 4. pp. 399-402.
@article{e918f142046e4fdab30e71a19a980c5b,
title = "Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer",
abstract = "Cisplatin and irinotecan are reported to act synergistically. The authors have conducted a phase II trial combining cisplatin and irinotecan in patients with refractory lung cancer to evaluate the activity and safety of the regimen. Twenty-one patients, who had not responded to prior platinum- based chemotherapy, were entered into the study. Both cisplatin (30 mg/m2) and irinotecan (60 mg/m2) were administrated on days 1, 8, and 15, and the regimen was repeated every 28 days. There were six partial responses, and the response rate was 29{\%} (95{\%} confidence interval, 11.3{\%}-52.2{\%}). The median survival time of all patients was 32 weeks, and 1-year and 2-year survival rates were 43{\%} and 11{\%}, respectively. Major toxicities were hematologic; leukopenia of grades 3 and 4 developed in 43{\%} patients, anemia developed in 38{\%}, and thrombocytopenia developed in 19{\%}. One notable nonhematologic toxicity was diarrhea; which was grade 3 in 38{\%}. The weekly chemotherapy combining cisplatin and irinotecan was active against lung cancer, which is refractory to platinum-based chemotherapy. However, skips of drag administration or dose reduction were necessary in 76{\%} patients during two courses of planned administration, though the ratio of actual dose to scheduled dose was 81{\%}. Dose modification would be necessary to yield better results by this weekly chemotherapy.",
author = "Yoichi Nakanishi and Koichi Takayama and Koichi Takano and Kohji Inoue and Shin'ichi Osaki and Hiroshi Wataya and Youichi Takaki and Takahiro Minami and Masayuki Kawasaki and Nobuyuki Hara",
year = "1999",
month = "8",
day = "1",
doi = "10.1097/00000421-199908000-00016",
language = "English",
volume = "22",
pages = "399--402",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

AU - Nakanishi, Yoichi

AU - Takayama, Koichi

AU - Takano, Koichi

AU - Inoue, Kohji

AU - Osaki, Shin'ichi

AU - Wataya, Hiroshi

AU - Takaki, Youichi

AU - Minami, Takahiro

AU - Kawasaki, Masayuki

AU - Hara, Nobuyuki

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Cisplatin and irinotecan are reported to act synergistically. The authors have conducted a phase II trial combining cisplatin and irinotecan in patients with refractory lung cancer to evaluate the activity and safety of the regimen. Twenty-one patients, who had not responded to prior platinum- based chemotherapy, were entered into the study. Both cisplatin (30 mg/m2) and irinotecan (60 mg/m2) were administrated on days 1, 8, and 15, and the regimen was repeated every 28 days. There were six partial responses, and the response rate was 29% (95% confidence interval, 11.3%-52.2%). The median survival time of all patients was 32 weeks, and 1-year and 2-year survival rates were 43% and 11%, respectively. Major toxicities were hematologic; leukopenia of grades 3 and 4 developed in 43% patients, anemia developed in 38%, and thrombocytopenia developed in 19%. One notable nonhematologic toxicity was diarrhea; which was grade 3 in 38%. The weekly chemotherapy combining cisplatin and irinotecan was active against lung cancer, which is refractory to platinum-based chemotherapy. However, skips of drag administration or dose reduction were necessary in 76% patients during two courses of planned administration, though the ratio of actual dose to scheduled dose was 81%. Dose modification would be necessary to yield better results by this weekly chemotherapy.

AB - Cisplatin and irinotecan are reported to act synergistically. The authors have conducted a phase II trial combining cisplatin and irinotecan in patients with refractory lung cancer to evaluate the activity and safety of the regimen. Twenty-one patients, who had not responded to prior platinum- based chemotherapy, were entered into the study. Both cisplatin (30 mg/m2) and irinotecan (60 mg/m2) were administrated on days 1, 8, and 15, and the regimen was repeated every 28 days. There were six partial responses, and the response rate was 29% (95% confidence interval, 11.3%-52.2%). The median survival time of all patients was 32 weeks, and 1-year and 2-year survival rates were 43% and 11%, respectively. Major toxicities were hematologic; leukopenia of grades 3 and 4 developed in 43% patients, anemia developed in 38%, and thrombocytopenia developed in 19%. One notable nonhematologic toxicity was diarrhea; which was grade 3 in 38%. The weekly chemotherapy combining cisplatin and irinotecan was active against lung cancer, which is refractory to platinum-based chemotherapy. However, skips of drag administration or dose reduction were necessary in 76% patients during two courses of planned administration, though the ratio of actual dose to scheduled dose was 81%. Dose modification would be necessary to yield better results by this weekly chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0033508623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033508623&partnerID=8YFLogxK

U2 - 10.1097/00000421-199908000-00016

DO - 10.1097/00000421-199908000-00016

M3 - Article

C2 - 10440199

AN - SCOPUS:0033508623

VL - 22

SP - 399

EP - 402

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -